 Sanofi SNY, 0.38 SAN, 3.70 and GlaxoSmithKline GSK, 1.86 said Friday that their experimental bivalent COVID-19 booster had a 72 efficacy rate against omicron, and they now plan to submit the data to regulators. The recombinant protein booster protects against the original strain of the virus as well as the beta variant, a strain of the virus that is no longer in circulation but that shares mutations with omicron that allow both variants to escape antibodies. 